SYS-CON MEDIA Authors: Bob Gourley, Sandi Mappic, Eric Brown, RealWire News Distribution, Kevin Benedict

News Feed Item

Interim Clinical Study Results, Leadership Appointments, and Earnings Release Schedules - Analyst Notes on Merck, Magellan, ABIOMED, CONMED, and Greatbatch

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, April 15, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Magellan Health Services Inc. (NASDAQ: MGLN), ABIOMED, Inc. (NASDAQ: ABMD), CONMED Corporation (NASDAQ: CNMD), and Greatbatch, Inc. (NYSE: GB). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1143-100free

Merck & Co., Inc. Analyst Notes 

On April 11, 2014, Merck & Co., Inc. (Merck) announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172 and MK-8742 among patients with chronic HCV Genotype 1 infection. According to the release, hard-to-cure patients who were administered MK-5172/MK-8742 with and without ribavirin (RBV) for 12 or 18 weeks have shown sustained viral response, 4 to 8 weeks after the completion of therapy. Dr. Eric Lawitz, MD, Vice President of Scientific and Research Development at The Texas Liver Institute, and Clinical Professor of Medicine at University of Texas Health Science Center in San Antonio said, "There is still a need for further options for the most difficult-to-cure patients, including those with cirrhosis and HCV/HIV co-infection, These findings provide additional clinical evidence regarding the potential of MK-5172/MK-8742 in treating a broad spectrum of HCV patients." The full analyst notes on Merck & Co., Inc. are available to download free of charge at:

http://www.analystsreview.com/1143-MRK-.pdf

Magellan Health Services Inc. Analyst Notes 

On April 7, 2014, Magellan Health Services, Inc. (Magellan) announced the appointment of Daniel M. Parietti as CEO of AlphaCare, 65% of which is owned by Magellan under a strategic investment which was completed in December 2013. The Company stated that under the new role which is effective from the announcement date, Parietti reports directly to Scott Markovich, President of Magellan Complete Care. "Daniel has an extensive background leading large successful health plan businesses. His experience and proven track record, coupled with AlphaCare's involvement in the New York market, will help us grow our presence there," said Markovich. Magellan informed that prior to joining AlphaCare, Parietti worked with Centene Inc. (Centene) where he had executive leadership and profit and loss responsibility for health plans in seven states. The full analyst notes on Magellan Health Services Inc. are available to download free of charge at:

http://www.analystsreview.com/1143-MGLN-.pdf  

ABIOMED, Inc. Analyst Notes 

On April 10, 2014, ABIOMED, Inc. (ABIOMED) announced that it intends to release Q4 FY 2014 (period ended March 31, 2014) financial results on May 1, 2014. The Company stated that it has scheduled a conference call at 8:00 a.m. ET on the same day to discuss the results. ABIOMED informed that the conference call will be hosted by the Company's Chairman, President, and CEO, Michael R. Minogue; and Vice President and CFO, Robert L. Bowen. The Company noted that the live webcast of the call will be available under the Investors section of its website and replay of this conference call will be available beginning at 11:00 a.m. ET May 1, 2014 through 11:59 p.m. ET on May 8, 2014. The full analyst notes on ABIOMED, Inc. are available to download free of charge at:

http://www.analystsreview.com/1143-ABMD-.pdf

CONMED Corporation Analyst Notes 

On April 7, 2014, CONMED Corporation (CONMED) announced that it intends to release Q1 2014 financial results on April 24, 2014, before the market opens. The Company stated that it has scheduled a conference call on the same day, which will be broadcast live over the Internet at 10:00 a.m. ET, to discuss the results. The Company informed that this webcast can be accessed from CONMED's web site and replay of the call will be made available through May 2, 2014.The full analyst notes on CONMED Corporation are available to download free of charge at:

http://www.analystsreview.com/1143-CNMD-.pdf

Greatbatch, Inc. Analyst Notes 

On March 31, 2014, Greatbatch, Inc. (Greatbatch) announced that will report its Q1 FY 2014 (period ended April 4, 2014) financial results through a press release on April 30, 2014, after the market closing. The Company stated that on the same day it has scheduled a conference call at 5:00 p.m. ET to discuss the results. Greatbatch added that the earnings conference call can be accessed from the Company's website. The full analyst notes on Greatbatch, Inc. are available to download free of charge at:

http://www.analystsreview.com/1143-GB-.pdf

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES: 

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.analystsreview.com/


SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.